This BCC Research report explores the present and future strategies within the manufacturing of the protein drugs market, which includes peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. Forecast provided from 2015 through 2020.
Use this report to:
Explore present and future strategies within manufacturing of the protein drugs market. Analyze the protein drug market and its applications, regulatory environment, technology, market projections and market shares. Gain information about the history of therapeutic proteins and its manufacturing technologies. Relevant patent analysis and profiles of companies that lead manufacturing in the protein drug industry
The global protein drugs market reached nearly $174.7 billion in 2015 and should reach nearly $248.7 billion by 2020 increasing at a compound annual growth rate (CAGR) of 7.3% through 2020. The U.S., leader in the protein drugs market, reached nearly $92.0 billion in 2015 and should reach $154.1 billion by 2020 at a CAGR of 10.9% through 2020. Europe as a segment reached $42.2 billion in 2015 and should reach $48.1 billion by 2020, at a CAGR of 2.6% through 2020.
Proteins play the most diverse role in the body. Protein drug products have many advantages over small-molecule drugs; their actions are highly specific and they are less likely to interfere with normal biological processes, and are often well tolerated by the body. The protein drug market is highly segmented and promising. Protein drugs can be manufactured through many different ways. They are either created through recombinant deoxyribonucleic acid (rDNA) technology, or can be isolated as naturally occurring substances from animals, microorganisms and insects. BCC Research’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for manufacturing of protein drugs.
This report explores the present and future strategies within the manufacturing of the protein drugs market, which includes peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. The history of the market, the restraining factors and the needs of the market are discussed in this report. The classification of these products and their manufacturing processes are also detailed in this report.
An analysis of the industry structure of protein drug products has been conducted.
Revenues are broken down by region. Sales figures are estimated for the five-year period from 2015 through 2020. The market by manufacturing process for these protein drugs is discussed separately in the report. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THIS STUDY
Protein drugs play an important role in the biopharmaceutical industry. The increase in incidences of chronic diseases such as cancer, various hormone and enzymatic disorders, asthma and autoimmune diseases have added to the growth of the protein drug market. Outstanding improvements in technologies such as mass spectrometry, advances in molecular genetics, and progress in production technologies are driving the market’s growth. Extensive research in the manufacturing process of protein drugs has revealed their usage in developing efficient, user-friendly and affordable products.
Modern industries have now begun to explore the advantages of these technologies for manufacturing protein drugs in their productions and processes.
R&D spending, along with increasing competition, patent expiries and new technologies are giving a new direction to the market. The advancements, new product launches and the changing lifestyle have influenced the market to grow in the future.
This study looks at almost all the systems affected by these factors. Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type in light of the new technologies, growing competition, and changing customer needs.
SCOPE OF THE STUDY
The scope of this study covers manufacturing of protein drugs technologies. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. This report covers the currently used six techniques in manufacturing of protein therapeutics, which includes fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. The protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes and blood factors. The market is also analyzed on the basis of the manufacturing process used in making therapeutic protein drugs.
Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the manufacturing of the protein drug industry. Some of the major players of the market include Eli Lilly & Co., Abbvie Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Novo Nordisk AG, Novartis AG, Merck & Co., Merck KGaA and Amgen Inc..
Our reports have been used by over 10K customers, including:
Peritonitis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Pipeline Review, H2 2018, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape. Peritonitis is inflammation of the peritoneum....
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 22.214.171.124) - Pipeline Review, H2 2018 Summary High Affinity Nerve...
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 188.8.131.52) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed...
116 pages •
By Infiniti Research Limited
• Nov 2018
About Hydronephrosis Hydronephrosis is a condition when the inside of the kidney gets dilated or stretched and usually analgesics and drugs for kidney stones are used as therapeutics for hydronephrosis. Technavio’s analysts forecast the Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the...
With the first prophylactic cancer vaccine Gardasil approved in 2006 and therapeutic cancer vaccine Sipuleucel-T (Provenge) approved in 2010, cancer vaccines is a proven hot treatment modality which is now turbocharged with the event of immune-checkpoint inhibitors. Cancer Vaccines: Analytical Tool is the most up to date and comprehensive...
The first Antibody-Drug Conjugate (ADC) to receive marketing approval from the US Food and Drug Administration (FDA) was gemtuzumab ozogamicin (Mylotarg) in 2000 which represents a powerful, emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. Conjugated...